Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study – Clinical and Experimental Medicine

Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate whether vaccination and monoclonal antibodies (mAbs) have modified the outcomes of HM patients with COVID-19. This is a single-centre retrospective study in HM patients hospitalized due to SARS-CoV-2 infection from March 2020 to…

Read the full article here

Source: SpringerLink

Categories: Hem/Oncs, Latest Headlines

Tags: bmtsm, covid19, COVID19nCancer, leusm, lymsm, mmsm, mpnsm

Tweets with this article

Mike Thompson, MD, PhD, FASCO

Outcome of #COVID19 Pts w/ haematological malignancies after the intro of vaccination & monoclonal antibodies: results from HM-COV 2.0 study [Mar 3, 2023] Oliva et al. Clinical and Experimental Medicine https://t.co/5D0QY2Qmmw #COVID19nCancer #bmtsm #leusm #lymsm #mmsm #mpnsm

COVID-19 vaccination and breakthrough infections in patients with cancer

Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of…

Mike Thompson, MD, PhD, FASCO April 18, 2024

The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19

Background Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a…

Mike Thompson, MD, PhD, FASCO April 18, 2024

COVID-19 and Cancer—A Review of the Registry-Based Pandemic Response

This review describes the registry efforts made during the COVID-19 pandemic with the aim of investigating and sharing information about the history, risk factors, and…

Mike Thompson, MD, PhD, FASCO April 18, 2024

The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study

Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.

Mike Thompson, MD, PhD, FASCO April 18, 2024

Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study

AbstractBackground. The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronaviru

Mike Thompson, MD, PhD, FASCO April 18, 2024

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of…

Mike Thompson, MD, PhD, FASCO April 18, 2024

Related Articles